CGP

Creta, Thomas Vu, and Lloyds Investment Group Join Forces to Launch $1 Billion Fund, Accelerating Global Growth of Web3 Game Industry

Retrieved on: 
Wednesday, February 14, 2024
Netflix, USD, Battle Royale, AI, League, Growth, Monster Strike, CGP, CCR, Resident Evil, Street Fighter II, Binance, League of Legends, Fintech, NFT, Leisure, Fund, Ecosystem, Executive producer, Arcane, Triple, Partnership, Video game

This collaboration underscores Creta's commitment to driving growth and innovation in the Web3 gaming market across the MENA region.

Key Points: 
  • This collaboration underscores Creta's commitment to driving growth and innovation in the Web3 gaming market across the MENA region.
  • It is envisioned that games will form integral components of the Creta Multiverse and Platform, presenting opportunities beyond the current $300 billion gaming industry.
  • Locus Chain, a pioneering blockchain protocol, renowned for its revolutionary approach in replacing central game servers, is joining the newly established fund.
  • By aligning with this initiative, Locus Chain reaffirms its commitment to driving innovation and fostering growth alongside Creta's partners.

AMERICAN GROUP PSYCHOTHERAPY ASSOCIATION ANNOUNCES LAUNCH OF EVIDENCE-BASED GROUP TREATMENT WEBSITE

Retrieved on: 
Monday, February 12, 2024
Private practice, Mental health, Doctor of Philosophy, American Psychological Association, American Group Psychotherapy Association, Psycho-oncology, CGP, Mental, DSM-IV codes, Society, Convention center, American Psychologist, Depression, Group Therapy, Social anxiety, Meta-analysis, Workforce, Brigham Young University, AGPA

NEW YORK, Feb. 12, 2024 /PRNewswire/ -- The American Group Psychotherapy Association announced the launch of an Evidence-Based Group Treatment Website at https://evidencebasedgrouptherapy.org/.

Key Points: 
  • Group Therapy Will be Key for Mental Health Treatment Access and New Website Will Serve as a Resource for Effective, Disorder Specific Group Treatments Supported by Evidence
    This website has been developed by an international team of renowned mental health professionals and supported by the American Psychological Association's Society of Group Psychology and Group Psychotherapy (Division 49), the American Group Psychotherapy Association (AGPA) with funding provided by the Group Foundation for Advancing Mental Health, and the German Health Ministry.
  • The use of group can address this issue, and this website can serve as a resource for treatment information and the basis of trainings to increase practitioner's comfort in providing group therapy.
  • Moreover, agencies who provide the highest percentage of group treatment in the US could extend their group treatment offerings by employing evidence-based protocols found on the website for the most common psychiatric disorders.
  • This website is a valuable resource in providing access to information on the most effective treatments for common mental health challenges."

Creta and Republic Form Strategic Partnership to Revolutionize Web3 and Metaverse Gaming

Retrieved on: 
Wednesday, February 7, 2024
Crypto, Partnership, Avalanche, Growth, Family, Street Fighter II, AngelList, League, CGP, Battle Royale, Celestial cartography, Riot Games, Ecosystem, Marketing, CCR, Investment, Morgan Stanley, Polygon, Sale, NFT, Monster Strike, K/DA, Resident Evil, Cryptocurrency

Creta is a global Web3 metaverse gaming platform headquartered in the UAE with offices in Japan and Armenia.

Key Points: 
  • Creta is a global Web3 metaverse gaming platform headquartered in the UAE with offices in Japan and Armenia.
  • The Creta platform is developed by Diverse, a South Korean company specializing in metaverse games with a high-performance game engine and excellent graphics technology.
  • As a discerning force in the Web3 landscape, Republic is selective and strategic in their partnerships.
  • Republic is dedicated to fostering the Web3 ecosystem alongside Creta, and their partnership will involve advisory services, research-driven token economics, and investment facilitation.

Creta Partners with Lloyd Investment Group in Establishing a Fund to Enhance the Growth of Web3 Gaming Industry

Retrieved on: 
Wednesday, February 7, 2024
Partnership, Fund, Growth, Life, Street Fighter II, League, CGP, Battle Royale, Marketing, CCR, Monster Strike, NFT, Resident Evil, Leisure, Video game

This collaboration involves the establishment of a new fund, currently valued at $1 billion, aimed at propelling the growth of the Web3 gaming industry across the MENA region.

Key Points: 
  • This collaboration involves the establishment of a new fund, currently valued at $1 billion, aimed at propelling the growth of the Web3 gaming industry across the MENA region.
  • The newly established fund will provide grants to emerging developers, enabling them to bring their game concepts to life.
  • With a cutting-edge gaming and entertainment platform, Creta aims to lead the next generation of game and metaverse content industries.
  • The new fund aims to expand the Creta metaverse by developing content and cultivating a pool of skilled developers.

Port Houston Community Grants Program Application Period Opens February 1

Retrieved on: 
Tuesday, January 16, 2024
Education, Professional Services, Other Transport, Philanthropy, Maritime, Other Philanthropy, Transport, Other Professional Services, Logistics, Supply Chain Management, Finance, Continuing, Organization, Workforce, LOI, CGP

Port Houston has announced the start of the application period for its Community Grants Program (CGP), beginning February 1.

Key Points: 
  • Port Houston has announced the start of the application period for its Community Grants Program (CGP), beginning February 1.
  • Port Houston is dedicated to supporting and helping improve the communities around the Houston Ship Channel.
  • Its Community Grants Program focuses on investing resources into meaningful projects and programs in our area.
  • Interested non-profits may access more information about Port Houston’s 2024 Community Grants Program, including dates, times, and links to the workshops, which can be found at https://porthouston.com/community/outreach/community-grants-program/

Ameriwest Lithium Provides Update on Its Thompson Valley Lithium Project, AZ

Retrieved on: 
Thursday, January 11, 2024
Lithium, ASM, ROW, Thompson Valley, Virginia, Reserve, CIM, Mining, Arizona Department, Mesa, OTC, CGP, Disclosure, Checklist, BLM, Arizona State University, GFOP, National instrument, News, Mineral Resources Limited, RC, Atmosphere

This is a major milestone in acquiring approvals necessary for a Phase 1 drilling program at the TV Project.

Key Points: 
  • This is a major milestone in acquiring approvals necessary for a Phase 1 drilling program at the TV Project.
  • The SUAs include the provisions for:
    A written plan for review and approval by the ranchers, with approval to not be unreasonably withheld.
  • Payment to the ranchers for land disturbance for building roads, trenches, and drill pads on a per length or per pad basis.
  • Begin to define the dimensions of the potential lithium deposit with the longer term goal of defining a lithium resource.

BostonGene Wins Fierce Life Sciences Innovation Award for AI-Driven Clinical Trials Matching Algorithm

Retrieved on: 
Wednesday, November 29, 2023
Research, Technology, Clinical Trials, Software, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, CGP, Data management, Data science, Clinical trial, Patient, Tumor microenvironment, Intelligence, Machine learning, Data collection, TME, MD, Comprehension, SVP, RNA-Seq, Pharmaceutical industry, Medical imaging

BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, announced today that it has won the 2023 Fierce Life Sciences Innovation Award for its AI-driven clinical trials selection tool.

Key Points: 
  • BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, announced today that it has won the 2023 Fierce Life Sciences Innovation Award for its AI-driven clinical trials selection tool.
  • The program, produced by Fierce Biotech and Fierce Pharma, recognizes innovations that exemplify effectiveness, technical innovation, competitive advantage, financial impact, and true innovation with the potential to transform the industry.
  • BostonGene has developed a proprietary AI-driven clinical trials matching algorithm, seamlessly integrated into the BostonGene Tumor Portrait™ test, a comprehensive genomic profiling (CGP) solution for oncology patients.
  • This algorithm relies on more than 80 dynamic parameters for personalized clinical trial recommendations.

Illumina launches advanced liquid biopsy assay to enable comprehensive genomic profiling of solid tumors

Retrieved on: 
Wednesday, November 1, 2023
MIT EAD Airframe Version 2, Pathology, Non-small-cell lung cancer, Medical laboratory, CGP, Nucleic acid thermodynamics, Research, Circulating tumor DNA, Illumina, Inc., Medicine, National Cancer Institute, TSO, Blood, Workflow, University, Chemistry, Liquid biopsy, Neoplasm, SAN, DNA, Automation, Medical imaging, Food delivery, Illumina

SAN DIEGO, Nov. 1, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation of its distributed liquid biopsy assay for genomic profiling. The new TruSight™ Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not available, or to complement tissue-based testing.

Key Points: 
  • SAN DIEGO, Nov. 1, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation of its distributed liquid biopsy assay for genomic profiling.
  • The new TruSight™ Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not available, or to complement tissue-based testing.
  • Growing evidence on the utility and efficacy of liquid biopsy CGP is leading to its inclusion in recommended professional guidelines in oncology.
  • Most notably, liquid biopsy testing in non-small-cell lung cancer has proven useful when tissue results are either unavailable or delayed.

EmeritusDX appoints Dr. Vincent Funari, Renowned Genomics and Bioinformatics Expert, as Chief Scientific Officer

Retrieved on: 
Monday, October 30, 2023
CGP, Publication, PCR, Microorganism, Health, California Department of Health Care Services, Research, Cedars-Sinai Medical Center, Genomics, Cell, Medicine, NEJM, LDT, UCLA, NeoGenomics, Cancer, Clinical Genetics (journal), Patient, California Department, Medical device, Science, Grand

LAKE FOREST, Calif., Oct. 30, 2023 /PRNewswire-PRWeb/ -- EmeritusDX, a rapidly growing cancer diagnostic and information company, proudly announces the appointment of Dr. Vincent Funari, Ph.D. to its executive team. Effective October 30th, Dr. Funari will serve as the Chief Scientific Officer, bringing with him an extensive background in genomics and precision medicine.

Key Points: 
  • Effective October 30th, Dr. Funari will serve as the Chief Scientific Officer, bringing with him an extensive background in genomics and precision medicine.
  • "I am extremely excited to deploy cutting-edge technology to impact the patients with cancer that EmeritusDX serves."
  • Before this role, he contributed significantly as the Chief Scientific Officer at NeoGenomics, overseeing the successful launch of several comprehensive genomic panels(CGP).
  • Robert Embree, Chief Executive Officer of EmeritusDX, expressed the company's excitement: "EmeritusDX is thrilled to have such a well-respected genomics authority like Dr. Funari leading our research and innovation teams.

New Research from Foundation Medicine and Roche Demonstrates Improved Outcomes Following Treatment Based on Comprehensive Genomic Profiling in Patients with Cancer of Unknown Primary Origin (CUP)

Retrieved on: 
Friday, October 20, 2023
Biotechnology, Genetics, Health, Oncology, Neoplasm, Patient, Survival, FDA, ESMO, Food, Progression-free survival, CGP, CUP, European Society for Medical Oncology, Foundation Medicine, MD, Doctor of Philosophy, Research, Liquid, Radiation, Roche, Safety, Cancer, Diagnosis, Pharmaceutical industry

These patients have a high unmet medical need due to the lack of a definitive diagnosis of a primary tumor site.

Key Points: 
  • These patients have a high unmet medical need due to the lack of a definitive diagnosis of a primary tumor site.
  • Because the cancer’s tumor of origin is unknown, targeted treatment has historically been challenging.
  • “Patients with CUP do not have many treatment options, so we set out to investigate how implementing comprehensive genomic profiling could impact outcomes,” said Dr. Jeffrey Ross, Medical Director at Foundation Medicine.
  • Patients achieving disease control were randomized 3:1 to targeted therapy informed by comprehensive genomic profiling versus chemotherapy continuation for at least three further cycles.